In Monday’s session, if Nifty continues to trend northwards tracking Friday’s optimism, then we hold 11030-11080 as the major resistances, followed by 11120. However, if Nifty retreats from here, we hold 10980-10925 as the major support area followed by 10880 level.

Indian stock markets are likely to open on a flat to negative note tracking weak global cues and negative start from the Asian peers. The trading of Nifty 50 index future on the Singapore stock exchange is trailing flat indicates that Nifty could open flat at the opening bell. 

In a mutual fund scheme, you may have the option of choosing a dividend plan or a systematic withdrawal plan (SWP). If you are new to mutual fund investing, such an option may leave you confused and you may not be able to decide which one to go for. Let us find out what these options entail and help you choose the one that meets your financial needs and goals.

Almost 50 years post the nationalisation of banks, the wheel has turned a full circle and we are now talking about privatisation of public sector banks! So, how have things changed over the years that the present government, as well as some of the previous governments, have sought to disown (disinvest) the public sector banks (PSBs).

Diversification is made out to be a panacea against the risk of volatility, be it volatility in prices of stocks on the stock markets or volatility in interest rates in debt market. But diversification is a broad concept that needs to be understood thoroughly by the investors. So let’s try to understand what is meant by diversification.

The Insurance Regulatory and Development Authority of India (IRDAI) had in January 2017 laid down guidelines for insurance companies about disclosures in respect of investments made by these companies in various other companies.

The people of India do not need such dramatized versions of performance evaluation by the opposition parties or by the government.  They live and experience the performance or non-performance of the government on a daily basis, so they will deliver their verdict as per their own parameters of performance assessment and according to their own political judgement. 

Jubilant Life Sciences has announced that its subsidiary Jubilant Pharma Limited has initiated Optimum trial, which is a pivotal Phase II clinical trial, designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma. This will be taking place through Jubilant Pharma's unit Jubilant DraxImage Inc. in Montreal, Canada.

Sanwaria Consumer Limited's standalone revenue for the first quarter of fiscal year 2019 has marginally increased by 4 per cent to Rs. 1,200.14 crore on YoY basis. EBITDA for the quarter has increased by 45.8 per cent to Rs. 60.15 crore as compared to same quarter of previous fiscal year.

On the last day of subscription, the IPO of TCNS Clothing Company was oversubscribed 4.52 times on Friday, 20 July. The price band of the IPO is Rs. 714-716 per share of face value Rs. 2, with a lot size of 20 equity shares.